PMID- 34315166
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2296-5262 (Electronic)
IS  - 2296-5270 (Linking)
VI  - 44
IP  - 9
DP  - 2021
TI  - Comparative Safety and Efficacy of Therapeutic Options in Resectable and 
      Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect 
      Comparison.
PG  - 476-484
LID - 10.1159/000517409 [doi]
AB  - OBJECTIVES: FOLFIRINOX, gemcitabine/nab-paclitaxel (gem-nab/P), and 
      gemcitabine-capecitabine (gem-cap) demonstrated superiority over gemcitabine 
      monotherapy for pancreatic cancer (PC). It is still unclear which chemotherapy 
      regimen is the most optimal. This study aimed to conduct a systematic review (SR) 
      and indirect comparison to compare safety and efficacy of FOLFIRINOX versus 
      gem-nab/P and gem-cap in PC. METHODS: An SR was conducted in several databases 
      from inception to November 2020. RCTs investigating resectable or advanced PC 
      were included. Primary outcomes including overall survival (OS), disease-free 
      survival (DFS)/progression-free survival (PFS)/relapse-free survival (RFS), and 
      grade 3/4 adverse events (AEs) were pooled using a random effects model. Indirect 
      comparisons were done to compare FOLFIRINOX versus gem-cap and gem-nab/P. 
      Heterogeneity was evaluated using Cochran's Q test and I2 statistics. RESULTS: 
      Nine studies were identified involving 6,564 patients. Indirect comparisons 
      showed FOLFIRINOX had significantly better OS (resectable: HR 0.78 [0.61-0.99]; 
      advanced: HR 0.71 [0.60-0.85]) and RFS/DFS/PFS (resectable: HR 0.67 [0.55-0.82]; 
      advanced: HR 0.65 [0.57-0.74]) compared to gem-cap as well as OS (resectable: HR 
      0.78 [0.61-1.00]; advanced: HR 0.73 [0.54-0.98]) and DFS/PFS (resectable: HR 0.66 
      [0.53-0.82]; advanced: HR 0.64 [0.49-0.83]) compared to gem-nab/P. FOLFIRINOX 
      increased grade 3/4 AE risk compared to gem-cap and gem-nab/P. CONCLUSIONS: 
      FOLFIRINOX is associated with significant survival benefits compared to gem-nab/P 
      and gem-cap. However, it is important to consider the increased grade 3/4 AE risk 
      associated with FOLFIRINOX.
CI  - (c) 2021 S. Karger AG, Basel.
FAU - Kharat, Aditi
AU  - Kharat A
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Brendle, Madeline
AU  - Brendle M
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Chhibber, Anindit
AU  - Chhibber A
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Chaiyakunapruk, Nathorn
AU  - Chaiyakunapruk N
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Biskupiak, Joseph
AU  - Biskupiak J
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah, USA.
LA  - eng
PT  - Systematic Review
DEP - 20210727
PL  - Switzerland
TA  - Oncol Res Treat
JT  - Oncology research and treatment
JID - 101627692
RN  - 0 (Albumins)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Albumins
MH  - *Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Disease-Free Survival
MH  - Humans
MH  - Paclitaxel/adverse effects
MH  - *Pancreatic Neoplasms/drug therapy
OTO - NOTNLM
OT  - Chemotherapy regimens
OT  - FOLFIRINOX
OT  - Gemcitabine nab-paclitaxel
OT  - Gemcitabine-capecitabine
OT  - Indirect comparisons
OT  - Pancreatic cancer
OT  - Systematic review
EDAT- 2021/07/28 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/07/27 20:32
PHST- 2021/03/05 00:00 [received]
PHST- 2021/05/25 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/07/27 20:32 [entrez]
AID - 000517409 [pii]
AID - 10.1159/000517409 [doi]
PST - ppublish
SO  - Oncol Res Treat. 2021;44(9):476-484. doi: 10.1159/000517409. Epub 2021 Jul 27.